175 completed. 175 Phase 3, 34 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 175 | Completed 175 |
| Phase 2 | 34 | Completed 34 |
Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Fecal microbiota transplantation - Liver Cirrhosis | Phase 3 | Completed | Cristian Ichim | 19 | 2024-08-05 | 2026-03-27 |
| A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. Elafibranor, Placebo - Primary Biliary Cholangitis | Phase 3 | Completed | Ipsen | 92 | 2024-07-09 | 2026-07-09 |
| Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) Seladelpar 10 mg, Placebo - Primary Biliary Cholangitis | Phase 3 | Completed | Gilead Sciences | 96 | 2023-09-05 | 2026-06-04 |
| LiveSMART Trial to Prevent Falls in Patients With Cirrhosis Enhanced Usual Care, Lactulose, Investigator recommended exercise - Cirrhosis, Liver, Portal Hypertension | Phase 3 | Completed | University of Michigan | 233 | 2023-06-13 | 2026-07-31 |
| A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia OsrHSA, Plasbumin®-20 - Hypoalbuminemia, Hepatic Cirrhosis | Phase 3 | Completed | Healthgen Biotechnology Corp. | 328 | 2023-04-10 | 2024-04-09 |
| Lung Point of Care Ultrasound to Guide Albumin Administration in Cirrhosis Lower albumin dosage - Cirrhosis, Cirrhosis Advanced | Phase 3 | Completed | Centro Medico Issemym | 72 | 2023-03-01 | 2025-07-18 |
| Opioid Sparing Anesthesia in Patients With Liver Cirrhosis Undergoing Liver Resection Opioid-based group (OB) (placebo/saline), Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ "dexmedetomidine hydrochloride" - Pfizer) and ketamine) - Liver Cirrhosis | Phase 3 | Completed | Cairo University | 100 | 2022-12-01 | 2023-08-08 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo - Pulmonary Sarcoidosis | Phase 3 | Completed | aTyr Pharma, Inc. | 268 | 2022-09-15 | 2026-06-04 |
| Allopurinol and Quality of Life in Liver Cirrhosis Allopurinol Tablet, Placebo - Cirrhosis, Liver | Phase 2 / Phase 3 | Completed | Tanta University | 100 | 2022-06-15 | 2023-10-31 |
| Allopurinol to Prevent Cirrhosis Related Morbidities Placebo, Allopurinol 300 MG - Cirrhosis | Phase 2 / Phase 3 | Completed | Tanta University | 100 | 2022-06-15 | 2026-11-04 |
| Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Allopurinol 300 MG, Atorvastatin 20mg, Placebo - Cirrhosis, Hepatic Encephalopathy | Phase 2 / Phase 3 | Completed | Tanta University | 165 | 2022-06-15 | 2026-11-17 |
| Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19 Longidaza®, Placebo - Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis | Phase 3 | Completed | NPO Petrovax | 392 | 2022-04-08 | 2025-06-03 |
| Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo - Primary Biliary Cholangitis | Phase 2 / Phase 3 | Completed | Zydus Therapeutics Inc. | 196 | 2022-04-01 | 2026-09-17 |
| Growth Hormone in Decompensated Liver Cirrhosis Growth Hormone - Liver Cirrhosis, Fibrosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 96 | 2022-02-01 | 2025-12-16 |
| Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital cyclosporine - COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome | Phase 3 | Completed | Alexandria University | 66 | 2022-01-03 | 2025-05-14 |
| Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. Hydronidone capsules, The placebo capsules - Liver Fibrosis | Phase 3 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 248 | 2021-12-30 | 2024-12-20 |
| A Trial to Improve Quality of Life in People With Cirrhosis Lactulose - Cirrhosis | Phase 2 / Phase 3 | Completed | University of Michigan | 56 | 2021-11-10 | 2023-11-21 |
| Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis Obeticholic Acid Tablets(OCA), UDCA, Placebo - Primary Biliary Cholangitis | Phase 3 | Completed | Nanjing Chia-tai Tianqing Pharmaceutical | 108 | 2021-09-23 | 2024-07-11 |
| Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) Linerixibat, Placebo - Pruritus | Phase 3 | Completed | GlaxoSmithKline | 238 | 2021-08-27 | 2026-07-22 |
| RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) Seladelpar 10 mg, Placebo, Seladelpar 5 mg - Primary Biliary Cholangitis | Phase 3 | Completed | Gilead Sciences | 193 | 2021-04-21 | 2024-09-05 |
Showing 20 of 175. Sign in to see all of them.
Liver Cirrhosis (47) · Hepatitis C (32) · Hepatitis C, Chronic (23) · Ascites (17) · Liver Cirrhosis, Biliary (17) · Pulmonary Fibrosis (16) · Hypertension, Portal (11) · Cicatrix (9) · Idiopathic Pulmonary Fibrosis (8) · Esophageal and Gastric Varices (7) · Cicatrix, Hypertrophic (6) · Liver Diseases (6) · Lung Diseases (6) · Lung Diseases, Interstitial (6)
Pathological Conditions, Signs and Symptoms (175) · Pathologic Processes (171) · Digestive System Diseases (112) · Liver Diseases (104) · Infections (47) · Virus Diseases (43) · Blood-Borne Infections (42) · Communicable Diseases (42) · Hepatitis (42) · Hepatitis, Viral, Human (41) · RNA Virus Infections (41) · Flaviviridae Infections (39) · Disease Attributes (28) · Chronic Disease (26)
Ribavirin (18) · Tolvaptan (8) · Sofosbuvir (6) · dasabuvir (6) · ombitasvir (6) · paritaprevir (6) · peginterferon alfa-2b (6) · Terlipressin (5) · sofosbuvir-velpatasvir drug combination (5) · Acetylcysteine (4) · Granulocyte Colony-Stimulating Factor (4) · glecaprevir and pibrentasvir (4) · peginterferon alfa-2a (4) · pirfenidone (4) · Allopurinol (3)
AbbVie (10) · Gilead Sciences (8) · Assistance Publique - Hôpitaux de Paris (7) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Merck Sharp & Dohme LLC (5) · Post Graduate Institute of Medical Education and Research, Chandigarh (5) · Genentech, Inc. (3) · Hospital Clinic of Barcelona (3) · Otsuka Pharmaceutical Co., Ltd. (3) · Tanta University (3) · Bambino Gesù Hospital and Research Institute (2) · Boehringer Ingelheim (2) · Catalysis SL (2) · Duke University (2) · GlaxoSmithKline (2)
United States (57) · France (32) · United Kingdom (26) · Spain (25) · Germany (24) · Canada (23) · Italy (21) · China (16) · Belgium (14) · Russia (12) · Japan (11) · Australia (10) · Israel (10) · Poland (10) · India (9)
Imre Noth, MD (3) · Eric Cohen, MD (2) · Fernando Martinez, MD (2) · Ganesh Raghu, MD (2) · James Loyd, MD (2) · Jay Ryu, MD (2) · Jesse Roman, MD (2) · Joe Lasky, MD (2) · John McNally, PhD (2)
PMID 27847279, PMID 28388260, PMID 26835133, PMID 35688625, PMID 36740893, PMID 37391667, PMID 17105757, PMID 21571362, PMID 22027579, PMID 24834811, PMID 24836310, PMID 25151571, PMID 25890798, PMID 26111071, PMID 26400368, PMID 26575258, PMID 26968970, PMID 27672117, PMID 27708114, PMID 28039616, PMID 28526798, PMID 30072107, PMID 30116539, PMID 30176872, PMID 30472023, PMID 30729456, PMID 30971229, PMID 31047956, PMID 31153107, PMID 31401786, PMID 31914963, PMID 32217654, PMID 33239000, PMID 33434107, PMID 33902584, PMID 37467180, PMID 42548365, PMID 10077078, PMID 11242330, PMID 11348456, PMID 12845617, PMID 16306520, PMID 16306522, PMID 16790698, PMID 17058231, PMID 17133492, PMID 17206944, PMID 17560680, PMID 17717203, PMID 17901414
2014 (6), 2016 (3), 2005 (2), 2009 (2), U10HL080413 (2), 2004 (1), 2019 (1), 2023 (1), R01DK046580 (1), R01DK046602 (1), R01DK051523 (1), R03DK055618 (1), U01HL060839 (1), U24HL145265 (1)